α-Asarone attenuates chronic sciatica by inhibiting peripheral sensitization and promoting neural repair

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Chronic sciatica is a debilitating condition characterized by persistent pain.
• Current treatments have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate the therapeutic potential of alpha-asarone in managing chronic sciatica.
• To elucidate the underlying mechanisms of alpha-asarone's effects on nerve inflammation and repair.

Main Methods:

• A rat model of chronic constriction injury (CCI) was established to induce sciatica.
• Groups included sham, CCI, pregabalin, and alpha-asarone treatments.
• Biochemical assays measured inflammatory markers (IL-1β, IL-6, TNF-α, CRP, LPS, IL-10) and ion channel expression (TRPA1, TRPM8, TRPV1-4).
• Histological analysis assessed sciatic nerve damage and Schwann cell proliferation.
• In vitro studies examined alpha-asarone's effect on lipopolysaccharide (LPS)-induced Schwann cell apoptosis via the TLR4/p38MAPK pathway.

Main Results:

• Alpha-asarone significantly alleviated thermal hyperalgesia in CCI rats.
• It reduced pro-inflammatory cytokines and LPS, while increasing IL-10 in serum.
• Alpha-asarone downregulated TRP channel and inflammatory gene expression in dorsal root ganglion neurons.
• Treatment promoted nerve structure recovery by reducing inflammation and enhancing Schwann cell proliferation.
• In vitro, alpha-asarone protected Schwann cells from LPS-induced apoptosis by modulating the TLR4/p38MAPK pathway.

Conclusions:

• Alpha-asarone demonstrates significant therapeutic effects against chronic sciatica.
• Its mechanisms involve reducing inflammation, inhibiting peripheral sensitization, and promoting nerve repair.
• Alpha-asarone represents a promising candidate for sciatica treatment.